Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 19 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 10745471

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  2. US 10736976

    Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  3. US 10736961

    Method of averting opioid addiction

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  4. US 10738124

    Anti-EGFRvIII antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  5. US 10738126

    Anti-GITR antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  6. US 10738130

    Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  7. US 10737113

    Human antibodies to PD-1

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  8. US 10730948

    Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted
  9. US 10730944

    Anti-CD8 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted
  10. US 10711032

    Steroids and protein-conjugates thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 14, 2020 · Expires Jul 9, 2040

    granted
  11. US 10689436

    Human antibodies to influenza hemagglutinin

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted
  12. US 10683354

    Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  13. US 10676530

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  14. US 10662244

    Methods for tumor treatment using CD3XCD20 bispecific antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 26, 2020 · Expires May 21, 2040

    granted
  15. US 10640566

    Nucleic acid molecules encoding antibodies to the human glucagon receptor

    REGENERON PHARMACEUTICALS, INC. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  16. US 10640558

    Anti-IL-25 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted
  17. US 10633434

    Anti-C5 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted
  18. US 10632194

    Anti-ErbB3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted
  19. US 10626173

    Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 21, 2020 · Expires Apr 16, 2040

    granted
  20. US 10618968

    Antigen-binding proteins that activate the leptin receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted
  21. US 10588940

    Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 17, 2020 · Expires Mar 12, 2040

    granted
  22. US 10582702

    Non-human animals having an engineered ANGPTL8 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 10, 2020 · Expires Mar 5, 2040

    granted
  23. US 10584173

    Nucleic acids encoding high affinity antibodies to human IL-6 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 10, 2020 · Expires Mar 5, 2040

    granted
  24. US 10570151

    Biologically active molecules, conjugates thereof, and therapeutic uses

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted